Copyright
©The Author(s) 2021.
World J Gastroenterol. Oct 28, 2021; 27(40): 6775-6793
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6775
Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6775
National clinical trial number | Sample | Phase | Settings | Drug | Results |
NCT01473940 | 21 | I | Advanced; Metastatic; Any line | Ipilimumab; Gemcitabine | OS 8,5 m (95%CI: 2.2-10.3) |
NCT00556023 | 34 | I | Metastatic Chemotherapy naïve | Tremelimumab Gemcitabine | OS 7.4 m (95%CI: 5.8-9.4) |
NCT02331251 | 81 | I/II | Metastatic (PDAC and other tumors) Chemotherapy naïve | Pembrolizumab; Nab-Paclitaxel Gemcitabine | OS 15 m (95%CI: 6.8-22.6) |
Beatty et al, Clin Cancer Res 2013; 19: 6286–6295 | 22 | I | Advanced; First line | CD40 agonist (CP-870893); Gemcitabine | PFS 5.2 m (95%CI: 1.9-7.4); OS 8.4 m (95%CI: 5.3-11.8); 1-y OS 28.6% |
NCT01413022 | 47 | I | Borderline; Locally advanced Chemotherapy naïve | CCR2 inhibitor (PF-04136309); FOLFIRINOX | Combination arm: 49% OR Chemotherapy arm: 0% OR |
NCT02268825 | 39 | I | Advanced; Metastatic (gastrointestinal malignancies) ; Any line | Pembrolizumab mFOLFOX | No results posted |
NCT02309177 | 138 | I | Advanced; Metastatic (PDAC and other tumors); Any treatment naive | Nivolumab; Nab-Paclitaxel Gemcitabine | No results posted |
NCT02077881 | 98 | I/II | Metastatic; First line | IDO inhibitor (indoximod); Nab-Paclitaxel; Gemcitabine | No results posted |
NCT04045730 | 17 | I/II | Metastatic First line | Gemcitabine; Nab-Pacliatxel; Pembrolizumab | PFS 9.1 m (95%CI: 4.9-13.3); OS 15 m (95%CI: 6.8-23) |
NCT03214250 | 30 | I | Metastatic; First line | Gemcitabine; Nab-Paclitaxel; Nivolumab; CD40 (agonistic monoclonal antibody) APX005M (sotigalimab) | Ongoing |
NCT02826486 | 80 | II | Metastatic; Any line | BL-8040; Pembrolizumab; Pegylated liposomal Irinotecan + 5FU | Disease Control Rate 34.5%; OS: 3.3 m Patients receiving study drugs as second-line therapy: 7.5 m |
- Citation: Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol 2021; 27(40): 6775-6793
- URL: https://www.wjgnet.com/1007-9327/full/v27/i40/6775.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i40.6775